BOULDER, Colo., Aug. 19, 2016 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from a Phase 2 study of ARRY-797 will be presented at the 2016 European Society of Cardiology (ESC) Congress, which will be held August 27 - 31, 2016 in Rome, Italy.

https://photos.prnewswire.com/prnvar/20121029/LA02195LOGO

POSTER PRESENTATION



    Title:      Phase 2 study of A797, an oral,
                selective p38 mitogen-activated
                protein kinase inhibitor, in patients
                with lamin A/C-related dilated
                cardiomyopathy (Abstract #P4981)

    Presenter: Calum A. MacRae, MD

    Date:      Tuesday, August 30, 10:19 a.m. CEST

Updated and additional data will be provided at the conference beyond what is included in the abstract.

All abstracts can be accessed through the ESC website, or on this web page: http://spo.escardio.org/default.aspx?eevtid=1127.

The ARRY-797 abstract can be found by clicking this LINK.

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Five registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162), encorafenib (LGX818) and selumetinib (AstraZeneca). For more information on Array, please go to www.arraybiopharma.com. 



    CONTACT:                        Tricia Haugeto

                                    (303) 386-1193

                                    thaugeto@arraybiopharma.com

Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-announces-clinical-data-presentation-on-arry-797-at-the-2016-european-society-of-cardiology-congress-300316027.html

SOURCE Array BioPharma